However , a 38 % remission rate has been recently reported in refractory MCL treated with temsirolimus , a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment , and a progression-free survival of 10 months .
O O O O O O O O O O O O O B-DiseaseOrPhenotypicFeature O O B-ChemicalEntity O O B-GeneOrGeneProduct O O O O O O O O O O O B-DiseaseOrPhenotypicFeature O O B-DiseaseOrPhenotypicFeature O O O O B-ChemicalEntity O O O O O O O O O O